CRNX
Price
$30.50
Change
-$0.35 (-1.13%)
Updated
Jun 18 closing price
Capitalization
2.86B
50 days until earnings call
MREO
Price
$2.87
Change
+$0.07 (+2.50%)
Updated
Jun 18 closing price
Capitalization
456.33M
110 days until earnings call
Interact to see
Advertisement

CRNX vs MREO

Header iconCRNX vs MREO Comparison
Open Charts CRNX vs MREOBanner chart's image
Crinetics Pharmaceuticals
Price$30.50
Change-$0.35 (-1.13%)
Volume$480.47K
Capitalization2.86B
Mereo BioPharma Group
Price$2.87
Change+$0.07 (+2.50%)
Volume$1.11M
Capitalization456.33M
CRNX vs MREO Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. MREO commentary
Jun 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and MREO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 20, 2025
Stock price -- (CRNX: $30.50 vs. MREO: $2.87)
Brand notoriety: CRNX and MREO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 61% vs. MREO: 83%
Market capitalization -- CRNX: $2.86B vs. MREO: $456.33M
CRNX [@Biotechnology] is valued at $2.86B. MREO’s [@Biotechnology] market capitalization is $456.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $335.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileMREO’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • MREO’s FA Score: 1 green, 4 red.
According to our system of comparison, MREO is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 3 TA indicator(s) are bullish while MREO’s TA Score has 5 bullish TA indicator(s).

  • CRNX’s TA Score: 3 bullish, 5 bearish.
  • MREO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MREO is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а -5.66% price change this week, while MREO (@Biotechnology) price change was +8.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +13.75%, and the average quarterly price growth was +8.90%.

Reported Earning Dates

CRNX is expected to report earnings on Aug 08, 2025.

MREO is expected to report earnings on Oct 07, 2025.

Industries' Descriptions

@Biotechnology (+7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.86B) has a higher market cap than MREO($456M). MREO YTD gains are higher at: -18.000 vs. CRNX (-40.348). MREO has higher annual earnings (EBITDA): -44.87M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. MREO (62.5M). MREO has less debt than CRNX: MREO (747K) vs CRNX (50.8M). CRNX has higher revenues than MREO: CRNX (760K) vs MREO (0).
CRNXMREOCRNX / MREO
Capitalization2.86B456M627%
EBITDA-373.49M-44.87M832%
Gain YTD-40.348-18.000224%
P/E RatioN/AN/A-
Revenue760K0-
Total Cash1.27B62.5M2,038%
Total Debt50.8M747K6,801%
FUNDAMENTALS RATINGS
CRNX vs MREO: Fundamental Ratings
CRNX
MREO
OUTLOOK RATING
1..100
6520
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
7067
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
8349
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (76) in the null industry is in the same range as CRNX (92) in the Pharmaceuticals Major industry. This means that MREO’s stock grew similarly to CRNX’s over the last 12 months.

MREO's Profit vs Risk Rating (67) in the null industry is in the same range as CRNX (70) in the Pharmaceuticals Major industry. This means that MREO’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as MREO (98) in the null industry. This means that CRNX’s stock grew similarly to MREO’s over the last 12 months.

MREO's Price Growth Rating (49) in the null industry is somewhat better than the same rating for CRNX (83) in the Pharmaceuticals Major industry. This means that MREO’s stock grew somewhat faster than CRNX’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that MREO’s stock grew significantly faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXMREO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 14 days ago
76%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYLDX159.48N/A
N/A
Rydex Dow 2x Strategy A
SOPAX30.49N/A
N/A
ClearBridge Dividend Strategy A
ERBCX18.21N/A
N/A
Eaton Vance RBA Equity Strategy Fd Cl C
MAIPX15.61N/A
N/A
MAI Managed Volatility Institutional
LOGWX28.39N/A
N/A
Lord Abbett Developing Growth F3

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-1.13%
XNCR - CRNX
59%
Loosely correlated
+0.60%
TRDA - CRNX
57%
Loosely correlated
-5.13%
IDYA - CRNX
56%
Loosely correlated
-0.27%
RVMD - CRNX
55%
Loosely correlated
+2.02%
DYN - CRNX
55%
Loosely correlated
-0.74%
More

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with CRNX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
+2.50%
CRNX - MREO
49%
Loosely correlated
-1.13%
TRDA - MREO
45%
Loosely correlated
-5.13%
IMTX - MREO
44%
Loosely correlated
-4.72%
KYMR - MREO
44%
Loosely correlated
+0.19%
IDYA - MREO
44%
Loosely correlated
-0.27%
More